We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03196765
Previous Study | Return to List | Next Study

Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03196765
Recruitment Status : Withdrawn (No funding)
First Posted : June 23, 2017
Last Update Posted : March 7, 2019
Information provided by (Responsible Party):
NeuroVia, Inc.

Brief Summary:
This is a phase I/II, open label dose escalation study of multiple dose levels of NV1205 with a long-term treatment phase.

Condition or disease Intervention/treatment Phase
X-Linked Adrenoleukodystrophy Drug: Sobetirome (NV1205) Phase 1 Phase 2

Detailed Description:

This study is to evaluate the safety, pharmacokinetics, and efficacy of NV1205 in pediatric patients diagnosed with childhood cerebral adrenoleukodystrophy (CCALD).

The study consists of:

  • Screening period: within 30 days of first dose
  • Main treatment period of 12 weeks (Part 1- from Screening to Week 12)
  • Long Term Treatment (LTT) period (Part 2- Week 13 through Week 96)

In Part 1, subjects will have an initial 4-week treatment period at the assigned dose and, if no safety concerns are noted, subjects continue for another 8 weeks of extended safety assessment.

There will be several cohorts of subjects enrolled. After each Cohort has completed the 4-week initial safety assessment, the safety data will be reviewed by an independent Data Safety Monitoring Board (DSMB) and, subject to DSMB recommendation, Cohort 2 will be enrolled and receive the next dose level. After Cohort 2 has completed 4 weeks of treatment, the DSMB will review all available safety data (Cohorts 1 and 2) and, subject to DSMB recommendation, Cohort 3 will be enrolled and receive the next dose level. Additional Cohorts may be enrolled at the recommendation of the DSMB with an incremental dose increase.

In Part 2, subjects will continue to receive treatment in the LTT period of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Sequential Assignment
Intervention Model Description: Sequential dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)
Estimated Study Start Date : August 2018
Estimated Primary Completion Date : December 1, 2020
Estimated Study Completion Date : December 1, 2020

Intervention Details:
  • Drug: Sobetirome (NV1205)
    Once a day oral dose of the study drug
    Other Name: NV1205

Primary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 2 years ]
    Adverse events

Secondary Outcome Measures :
  1. Area under the curve concentration of NV1205 in plasma [ Time Frame: 12 weeks ]
    A sparse sampling approach will be utilized to estimate a 24-hr area under the curve of NV1205 plasma concentration

Other Outcome Measures:
  1. Loes score [ Time Frame: 2 years ]
    Percent change from baseline in brain lesions assessed as Loes score will be calculated

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   4 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Males ≥4 years and <18 years of age
  2. CCALD diagnosis confirmed by genetic testing
  3. Loes score of >0 and ≤15
  4. Patients on VLCFA lowering agents such as Lorenzo's oil must stop the medication and have high VLCFA levels before enrollment

Exclusion Criteria:

  • Significant medical conditions such as heart, thyroid, or liver disease
  • HSCT recipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03196765

Layout table for location information
Hospital Austral
Buenos Aires, Argentina
Hospital General de ninos Pedro de Elizalde
Buenos Aires, Argentina
Australia, Victoria
Monash Health
Clayton, Victoria, Australia, 3168
Hospital Clínico San Borja Arriarán
Santiago, Chile
Hospital Dr. Luis Calvo Mackenna
Santiago, Chile
Fundacion Cardioinfantil
Bogotá, Colombia
Hôpital Bicêtre - Paris Sud
Paris, France
Russian Federation
Endocrinology Research Center
Moscow, Russian Federation
Moscow Morozov's Children Clinical Hospital
Moscow, Russian Federation
Saint Petersburg State Pediatric Medical University
Saint Petersburg, Russian Federation
National Children's Specialized Hospital 'OKHMATDET'
Kiev, Ukraine
United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Manchester Children's Hospital
Manchester, United Kingdom
Sponsors and Collaborators
NeuroVia, Inc.
Layout table for investigator information
Study Director: John Henderson, MD NeuroVia, Inc.
Layout table for additonal information
Responsible Party: NeuroVia, Inc.
ClinicalTrials.gov Identifier: NCT03196765    
Other Study ID Numbers: NV1205-009
First Posted: June 23, 2017    Key Record Dates
Last Update Posted: March 7, 2019
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by NeuroVia, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hereditary Central Nervous System Demyelinating Diseases
Demyelinating Diseases
Mental Retardation, X-Linked
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Metabolism, Inborn Errors
Peroxisomal Disorders
Metabolic Diseases
Adrenal Insufficiency
Adrenal Gland Diseases
Endocrine System Diseases